Clinical Protocol and Data Management (CPDM) Clinical Protocol and Data Management (CPDM) is made up of 131staff members (as of June 2014) who facilitate development, implementation, coordination, internal data monitoring, and completion of approximately 250 oncology-focused trials at UPCI and UPMC CC each year. These include UPCI institutional (i.e., investigator-initiated), multi-center cooperative group/National Clinical Trial Network (NCTN), consortium, and industry-sponsored trials. Since 2008, CPDM oversight has been provided by the UPCI Associate Director for Clinical Investigation, Adam Brufsky, MD, PhD (BOCP), a board-certified medical oncologist. Deidre Cleary, BSN, RN, was appointed as the Director of CPDM in March 2012, and Rita Johnson, RN, was appointed as the Associate Director of CPDM in May 2013. As the central location for information on all cancer protocols, CPDM uses the Clinical Trials Management Application (CTMA) database to provide UPCI clinical investigators and review and monitoring committees with updated lists of all currently active protocols, status reports of individual planned and active protocols, and other critical clinical trial reports. To enhance staff training, improve protocol compliance, and facilitate internal and external audits, the CPDM QA/QC, Education, and Compliance Department was implemented during the past Cancer Center Support Grant (CCSG) funding period.
The specific aims of CPDM are to: 1) Develop the National Clinical Trials Network Lead Academic Participating Site and Experimental Therapeutics-Clinical Trials Network Lead Academic Organization at UPCI. 2) Increase accruals to novel investigator-initiated trials, and enhance availability of trials throughout network sites; 3) Streamline pre-submission and protocol design and review infrastructure in order to decrease the time to clinical trial activation, 4) Evaluate, review, and solidify the formal internal education, training, and compliance programs for clinical researchers, 5) Continue to strengthen the Data Safety Monitoring Committee through expert leadership and improved reporting processes; 6) Enhance regular communication between all cancer-related research departments within the large academic medical center and university, 7) Continue to enhance the web-based Clinical Trials Management Application to allow for greater automation of processes and improved data capture, safety compliance, and report generation, 8) Build trust, comfort and familiarity between the UPCI and UPMC CC and underserved populations, most notably African Americans, and decrease disparities through community based educational programs and screening, 9) Increase knowledge of and access to clinical research among African American communities by identifying and removing barriers to care and patient navigation, 10) Increase awareness, among parents and other concerned individuals, that clinical trials are the standard of care for children with cancer and hematologic malignancies, and 11) Maintain our long-standing relationship with the Pennsylvania Department of the Health to ensure implementation and evaluation of the recently published 2013-2018 Pennsylvania Cancer Control Plan in the UPCI catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-27
Application #
8928845
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2015-08-01
Budget End
2016-07-31
Support Year
27
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :

Showing the most recent 10 out of 1187 publications